Neoadjuvant chemotherapy (NACT) has been regarded a standard treatment for advanced ovarian cancers for decades. Among patients who are poor candidates for primary debulking surgery (PDS), NACT is likely their only option in clinical practice. However, NACT failed to show any survival benefit in the reported randomized controlled trials (RCTs) and the meta-analyses, compared with PDS. This phenomenon raises concerns over the unfavorable influence of NACT, that is, the potential risk of inducing platinum resistance. In this review, we reveal the risk of NACT-related platinum resistance by summarizing the experimental and clinical evidence and discuss new attempts to avoid this phenomenon.

几十年来，新辅助化疗 (NACT) 一直被认为是晚期卵巢癌的标准治疗方法。在不适合初次减瘤手术 (PDS) 的患者中，NACT 可能是他们在临床实践中的唯一选择。然而，在报告的随机对照试验 (RCT) 和荟萃分析中，与 PDS 相比，NACT 未能显示任何生存获益。这种现象引起了人们对NACT的不利影响的担忧，即诱发铂电阻的潜在风险。在这篇综述中，我们通过总结实验和临床证据揭示了 NACT 相关铂耐药的风险，并讨论了避免这种现象的新尝试。